Phar­ma heavy­weight Pfiz­er step­ping in­to the prostate can­cer ring with Ab­b­Vie af­ter ink­ing a $4.2B al­liance with My­ovant

My­ovant $MY­OV is ring­ing out the old year with a big, new com­mer­cial part­ner.

Pfiz­er $PFE has stepped up with a $4.2 bil­lion deal to part­ner with the biotech on its new­ly ap­proved drug re­l­u­golix, freight­ing the deal up­front with $650 mil­lion in cash and an­oth­er $200 mil­lion re­served for reg­u­la­to­ry de­ci­sions as My­ovant looks to fol­low up its win for prostate can­cer with 2 oth­er OKs for uter­ine fi­broids and en­dometrio­sis.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN